111 related articles for article (PubMed ID: 6449134)
21. Possible differentiation of human acute myeloblastic leukemia cells by daily and intermittent administration of aclacinomycin-A.
Sakurai M; Sampi K; Hozumi M
Leuk Res; 1983; 7(2):139-43. PubMed ID: 6574295
[TBL] [Abstract][Full Text] [Related]
22. Phase I trial of aclacinomycin A.
Van Echo DA; Whitacre MY; Aisner J; Applefeld MM; Wiernik PH
Cancer Treat Rep; 1982 May; 66(5):1127-32. PubMed ID: 6952961
[TBL] [Abstract][Full Text] [Related]
23. [Treatment of refractory acute lymphocytic leukemia in childhood with BH-AC, ACM, 6-MP, and prednisolone].
Karube T; Maehara M; Ijima H; Muchi H
Rinsho Ketsueki; 1984 May; 25(5):613-8. PubMed ID: 6590894
[No Abstract] [Full Text] [Related]
24. Clinical studies of aclacinomycin A (ACM).
Majima H; Ohta K
Biomed Pharmacother; 1987; 41(5):233-7. PubMed ID: 3311189
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of aclacinomycin A in acute leukemia and various solid tumors.
Schütte J; Niederle N; Seeber S
J Cancer Res Clin Oncol; 1983; 105(2):162-5. PubMed ID: 6572190
[TBL] [Abstract][Full Text] [Related]
26. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
Early AP; Preisler HD; Slocum H; Rustum YM
Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
[TBL] [Abstract][Full Text] [Related]
27. [Full remission of acute non-lymphatic leukemia lasting for 16 months following combination therapy with aclacinomycin A].
Beck JD
Monatsschr Kinderheilkd; 1986 Aug; 134(8):547-9. PubMed ID: 3464845
[TBL] [Abstract][Full Text] [Related]
28. Clinical phase I study of aclacinomycin A by evaluation of an intermittent intravenous administration schedule.
Casper ES; Gralla RJ; Young CW
Cancer Res; 1981 Jun; 41(6):2417-20. PubMed ID: 6940656
[TBL] [Abstract][Full Text] [Related]
29. An effective salvage regimen with aclarubicin for daunorubicin-resistant acute non-lymphocytic leukemia in children.
Nibu K; Yanai F; Okamura J; Ikuno Y; Tasaka H; Matsuzaki A; Inada H; Eguchi H; Sakai R; Koga H
Pediatr Hematol Oncol; 1995; 12(3):251-8. PubMed ID: 7640178
[TBL] [Abstract][Full Text] [Related]
30. Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
Liu L; Qu Q; Jiao W; Zhang Y; Li X; Ding C; Wu D
Leuk Res; 2015 Aug; 39(8):805-11. PubMed ID: 26021434
[TBL] [Abstract][Full Text] [Related]
31. [Remission induction by ACM-A and BH-AC on acute promyelocytic leukemia which is resistant to DNR and CA (author's transl)].
Shimazaki C; Nakajima Y; Ura Y; Hamami T; Haruyama H; Isemura T; Nakagawa M; Ijichi H
Rinsho Ketsueki; 1981 Jul; 22(7):1116-22. PubMed ID: 6948970
[No Abstract] [Full Text] [Related]
32. [Studies on hematological diseases in elderly patients. Part 4: Chemotherapeutic effect of aclarubicin (ACR) on acute nonlymphocytic leukemia in the aged].
Yorimitsu S; Takahashi I; Lai M; Ohmoto E; Aoyama S; Inagaki T; Ueda I; Nishimura M; Nakada H; Nonaka K
Nihon Ronen Igakkai Zasshi; 1986 May; 23(3):302-8. PubMed ID: 3463814
[No Abstract] [Full Text] [Related]
33. Activity of indicine N-oxide in refractory acute leukemia.
Letendre L; Smithson WA; Gilchrist GS; Burgert EO; Hoagland CH; Ames MM; Powis G; Kovach JS
Cancer; 1981 Feb; 47(3):437-41. PubMed ID: 7013959
[TBL] [Abstract][Full Text] [Related]
34. Sequentially administered 5-azacitidine and amsacrine in refractory adult acute leukemia: a phase I-II trial of the Southeastern Cancer Study Group.
Winton EF; Hearn EB; Martelo O; Presant CA; Adler S; Vogler WR; Raney M; Logan T; Silberman HM; Omura GA
Cancer Treat Rep; 1985; 69(7-8):807-11. PubMed ID: 2410119
[TBL] [Abstract][Full Text] [Related]
35. Aclarubicin in the treatment of multiple myeloma.
Sezaki T; Adachi T; Ishii H; Asano K; Takahashi I; Kimura I
Jpn J Clin Oncol; 1984 Sep; 14(3):353-8. PubMed ID: 6384577
[TBL] [Abstract][Full Text] [Related]
36. [Evaluation of aclacinomycin-A in head and neck cancer].
Tsukuda M
Gan To Kagaku Ryoho; 1984 Nov; 11(11):2335-41. PubMed ID: 6594077
[TBL] [Abstract][Full Text] [Related]
37. Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.
Fukushima T; Kawabata H; Sawaki T; Satoh T; Nakamura T; Iwao H; Nakajima A; Sakai T; Miki M; Fujita Y; Tanaka M; Kawanami T; Masaki Y; Okazaki T; Umehara H
Anticancer Res; 2012 Apr; 32(4):1347-53. PubMed ID: 22493369
[TBL] [Abstract][Full Text] [Related]
38. Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial.
Pedersen-Bjergaard J; Brincker H; Ellegaard J; Drivsholm A; Freund L; Jensen KB; Jensen MK; Nissen NI
Cancer Treat Rep; 1984 Oct; 68(10):1233-8. PubMed ID: 6597002
[TBL] [Abstract][Full Text] [Related]
39. [Low-dose 4N-behenoyl-1-beta-D-arabinofuranosylcytosine (BHAC) in the treatment of atypical leukemia].
Takahashi I; Nakada H; Hayashi N; Sekito N; Inagaki T; Aoyama S; Nonaka K; Ohmoto E; Kobayashi Y; Uchida K
Gan To Kagaku Ryoho; 1986 Sep; 13(9):2780-5. PubMed ID: 3463249
[TBL] [Abstract][Full Text] [Related]
40. Possible differentiation treatment with aclacinomycin A in acute myelomonocytic leukemia refractory to conventional chemotherapy.
Sato S; Sakashita A; Ishiyama T; Nakamaki T; Hino K; Tomoyasu S; Tsuruoka N; Honma Y; Hozumi M
Anticancer Res; 1992; 12(2):371-6. PubMed ID: 1580553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
